- £1.84bn
- £893.83m
- $548.51m
REG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Update on Licensed Oncology Product in China
AnnouncementREG - Hutchmed China Ltd - Directorate change
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2025 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Global Trial of ATTC Candidate
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Final Results
AnnouncementRCS - Hutchmed China Ltd - Publication of Phase III Results in The Lancet
AnnouncementRCS - Hutchmed China Ltd - Positive Topline Results of Phase III Trial
AnnouncementRCS - Hutchmed China Ltd - Surufatinib + Camrelizumab PDAC Phase 3 initiation
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - China NDA Acceptance-Savolitinib in Gastric Cancer
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - NDA Acceptance in China for Fanregratinib
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Development of ATTC Candidate
AnnouncementREG - Hutchmed China Ltd - Expanded NRDL Coverage + CIDL Inclusion in China
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data at ESMO and ASH
AnnouncementRCS - Hutchmed China Ltd - Enrollment Complete in SAFFRON Global Phase III
Announcement